GPR40 agonist-SSTR5 antagonistic double-effect compound as well as preparation method and application thereof
By developing the GPR40-SSTR5 dual-activity compound and preparing it using a variety of chemical reaction methods, the dual activities of agonizing GPR40 and antagonizing SSTR5 were achieved, and the problems of hepatotoxicity and lack of dual-activity compound of GPR40 agonist in the prior art were solved, which significantly improved the Effects of treatment of type 2 diabetes and neurodegenerative diseases.
Patent Information
- Application Number
- CN202310607398.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-26
- Publication Date
- 2024-11-26
AI Technical Summary
Existing GPR40 agonists have hepatotoxicity problems in the treatment of type 2 diabetes and neurodegenerative diseases, and there is no effective dual-acting compound that can agonize GPR40 and antagonize SSTR5 simultaneously, limiting the therapeutic effect.
A class of GPR40-SSTR5 dual-acting compounds were developed, prepared by Mitsunobu reaction, nucleophilic substitution reaction and Buchwald reaction. They have the dual activities of agonizing GPR40 and antagonizing SSTR5, and are used to improve the secretion of gastrointestinal hormones such as GLP-1, thereby Treatment of type 2 diabetes, obesity and neurodegenerative diseases.
This compound can effectively improve the secretion level of gastrointestinal hormones such as GLP-1, significantly improve the therapeutic effect of type 2 diabetes and obesity, and has potential neuroprotective effects, avoiding hepatotoxicity problems.
Smart Images

Figure CN119019309A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the fields of pharmaceutical chemistry, pharmacology and pharmacotherapy, and specifically to a class of GPR40-SSTR5 dual-effect compounds as shown in general formula I and a preparation method thereof, a pharmaceutical composition with the class of compounds as active ingredients, and use of the compounds in preparing drugs for treating diseases in the field related to GPR40-SSTR5. Background Art
[0002] Free fatty acid receptor 1 (FFAR1), also known as a G protein-coupled receptor 40 (GPR40), is highly expressed in pancreatic β cells, intestinal L cells, K cells and I cells, and neurons. GPR40 has multiple physiological functions, the most important of which is blood glucose regulation. The expression of GPR40 varies with blood glucose concentration, that is, when blood glucose is at a normal level, the expression of GPR40 is low. When blood glucose concentration increases, the GPR40 receptor on the pancreatic β cells will be stimulated by endogenous fatty acids, which will promote the secretion of insulin by the pancreatic β cells and regulate blood glucose to normal levels. When blood glucose returns to normal levels, the expression of GPR40 will decrease, thereby greatly reducing the risk of hypoglycemia, which makes the development of GPR40 agonists as a treatment for type 2 diabetes very attractive. In addition, GPR40 full agonists also activate GPR40 receptors on gastrointestinal endocrine cells, which promote the secretion of incretin (GLP-1 and GIP) and the production of PYY. These hormones can indirectly promote the secretion of insulin by the pancreas, and also have physiological functions such as reducing appetite and delaying gastric emptying, which makes GPR40 agonists have the potential to treat obesity and type 2 diabetes. Based on its strong ability to control blood sugar levels, GPR40 is most widely studied for the treatment of type 2 diabetes. However, although many partial agonists and full agonists have reached the level of efficacy, there are still no marketed drugs. Among them, TAK-875 is the only partial agonist that has entered the third phase of clinical trials. It was forced to terminate its development due to its hepatotoxicity, but the cause of hepatotoxicity is generally recognized to be related to the drug structure of TAK-875. TAK-875 is slowly metabolized and easily accumulates in the liver, and the phase II metabolites are active metabolites, which cause hepatotoxicity. Secondly, GPR40 is also distributed in the central nervous system of the human brain. The brain tissue contains a large amount of endogenous fatty acids, among which docosahexaenoic acid (DHA) and arachidonic acid (AA) are the most abundant. DHA may relieve pain, promote neuronal differentiation, protect and form nerves by stimulating GPR40 receptors on the nerve center. It is worth noting that when the probability of neurodegenerative diseases in diabetic patients increases, the widespread expression of GPR40 in the nervous system indicates that it may be involved in regulating central degenerative diseases caused by chronic metabolic diseases, which makes GPR40 one of the potential targets for the treatment of neurodegenerative diseases (such as Alzheimer's disease). In addition, GPR40 is also involved in the process of cellular inflammation and has anti-inflammatory and anti-allergic effects; when inflammation or chronic metabolic diseases develop to the late stage of the disease, it is often accompanied by fibrosis of organs or tissues. Recent studies have shown that GPR40 agonists have anti-fibrotic effects in multiple organs, proving that GPR40 is involved in the pathway of fibrosis and may become one of the targets for the treatment of fibrosis-related diseases.
[0003] SSTR5, somatostatin receptor 5, is an inhibitory G (Gi) protein-coupled receptor, whose endogenous ligands are somatostatin-14 (SST-14) and somatostatin-28 (SST-28). SSTR5 is mainly distributed in the pituitary gland, gastrointestinal tract and pancreatic islets. When SST-14 or SST-28 binds to SSTR5, it can activate SSTR5 and mediate the inhibitory effect of hormone secretion. Among them, SSTR5 activation in the gastrointestinal tract can antagonize the secretion of gastrointestinal hormones such as GLP-1, GLP-2, GIP, PYY, CCK, etc.; SSTR5 activation in pancreatic islet tissue can inhibit the secretion of insulin. GLP-1 has multiple physiological functions, such as promoting blood sugar-dependent insulin secretion and inhibiting glucagon secretion, promoting satiety, slowing gastric emptying, and playing a protective role in the liver, kidneys, and myocardium; GLP-2 can promote small intestinal growth and nutrient absorption, which is essential for maintaining intestinal homeostasis; GIP has a synergistic effect with GLP-1 in blood sugar regulation; PYY can slow gastric emptying and promote satiety; CCK can promote gallbladder contraction and promote bile outflow from the gallbladder; insulin is mainly involved in glucose metabolism. Pharmacological studies have shown that antagonizing SSTR5 can relieve the inhibitory hormone secretion effect mediated by the binding of SST to SSTR5, so SSTR5 is regarded as a potential drug target for chronic metabolic diseases such as type 2 diabetes, non-alcoholic fatty liver / hepatitis, inflammatory bowel disease, obesity, gallstones, and primary cholangitis. In addition, animal experiments have shown that SSTR5 antagonists have significant synergistic effects with receptors that promote GLP-1 secretion (such as TGR5, GPR40, GPR119, GPR41 and GPR43) and DPP4 inhibitors that inhibit GLP-1 degradation. The combination of the three can greatly increase the level of GLP-1. Therefore, the development of compounds that have both GPR40 receptor agonist activity and SSTR5 antagonist activity can greatly promote the secretion of GLP-1 by L cells. Combined administration with DPP4 inhibitors is expected to achieve super-therapeutic levels of GLP-1 secretion, which can be used in the treatment of diseases such as type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), inflammatory bowel disease, and neurodegenerative diseases. Summary of the invention
[0004] One of the purposes of the present invention is to provide a GPR40-SSTR5 dual-effect compound, a solvent compound, a hydrate and a pharmaceutically acceptable salt represented by the following general formula (I):
[0005] Another object of the present invention is to provide a method for preparing the compound.
[0006] Another object of the present invention is to provide a pharmaceutical composition comprising the compound.
[0007] Another object of the present invention is to provide pharmaceutical uses of the compound or pharmaceutical composition.
[0008] According to one aspect of the present invention, a class of GPR40-SSTR5 dual-effect compounds, solvent compounds, hydrates and pharmaceutically acceptable salts thereof are provided as shown in the following general formula I:
[0009]
[0010] The A ring is shown in the following structure:
[0011]
[0012] X is:
[0013] -CH2-, -CH(CH3)-, -NH-, -N(CH3)-, or -O-;
[0014] R5 is H, C1-3 alkyl, or C3-C6 cycloalkyl;
[0015] m, n are integers from 1 to 2;
[0016] o is an integer from 0 to 2;
[0017] R1, R2, R3, and R4 are each independently hydrogen, C1-3 alkyl, C1-3 alkoxy, C3-6 cycloalkyl, halogen, trifluoromethyl, trifluoroethyl, hydroxyl, amine, amine substituted with one or two C1-3 alkyl, or substituted or unsubstituted C6-20 aromatic ring; wherein, in the case of substituted C6-20 aromatic ring, the substituent is halogen, C1-3 alkyl, C3-5 cycloalkyl, hydroxyl, amine, amine substituted with one or two C1-3 alkyl, trifluoromethyl, trifluoroethyl, or trifluoromethoxy. According to one embodiment of the present invention, wherein the A ring is shown in the following structure:
[0018]
[0019] X is:
[0020] -CH2-, -CH(CH3)-, -NH-, -N(CH3)-, or -O-;
[0021] R5 is H, C1-3 alkyl, or C3-C6 cycloalkyl;
[0022] m, n are integers from 1 to 2;
[0023] o is an integer from 0 to 2;
[0024] R1, R2, R3, and R4 are each independently hydrogen, C1-3 alkyl, C1-3 alkoxy, C3-6 cycloalkyl, halogen, trifluoromethyl, trifluoroethyl, or a substituted or unsubstituted C6-20 aromatic ring; wherein, in the case of a substituted C6-20 aromatic ring, the substituent is halogen, C1-3 alkyl, C3-5 cycloalkyl, hydroxyl, trifluoromethyl, or trifluoroethyl.
[0025] According to one embodiment of the present invention, the A ring has the following structure:
[0026]
[0027] X is:
[0028] -NH-, -N(CH3)-, or -O-;
[0029] R5 is H, or C3-C6 cycloalkyl;
[0030] m, n are integers from 1 to 2;
[0031] o is an integer from 0 to 2;
[0032] R1, R2, R3, and R4 are each independently hydrogen, C1-3 alkoxy, C3-6 cycloalkyl, trifluoromethyl, trifluoroethyl, or a substituted or unsubstituted C6-20 aromatic ring; wherein, in the case of a substituted C6-20 aromatic ring, the substituent is halogen.
[0033] According to one embodiment of the present invention, the A ring has the following structure:
[0034]
[0035] X is:
[0036] -NH-, -N(CH3)-, or -O-;
[0037] R5 is H, or C3-C6 cycloalkyl;
[0038] m, n are integers from 1 to 2;
[0039] o is an integer from 0 to 2;
[0040] R1, R2, R3, and R4 are each independently hydrogen, C1-3 alkoxy, C3-6 cycloalkyl, trifluoromethyl, trifluoroethyl, or a substituted or unsubstituted C6-20 aromatic ring; wherein, in the case of a substituted C6-20 aromatic ring, the substituent is halogen.
[0041] According to one embodiment of the present invention, the compound is one of the following compounds:
[0042]
[0043]
[0044]
[0045] According to one embodiment of the present invention, a method for preparing the above-mentioned compound is provided, characterized in that one or more of the following preparation methods are used:
[0046] Method 1: Preparation of the compound represented by general formula L-6
[0047]
[0048] wherein R1, R2, R3, R4, R5, m, n, and o are as defined above;
[0049] Compound L-1 is reacted with different linker fragments L-2 to obtain L-3 through Mitsunobu reaction; the Mitsunobu reaction is carried out by conventional methods in the art. L-1 and the corresponding alcohol linker fragment are dissolved in an organic solvent, triphenylphosphine and azo reagent are added, and the reaction is carried out at 0-60°C for 1-24 hours. The solvent can use any solvent that has no adverse effect on the reaction, preferably dichloromethane, tetrahydrofuran, etc. The azo reagent is diisopropyl azodicarboxylate, diethyl azodicarboxylate, N,N,N',N'-tetramethylazodicarboxamide, etc., preferably diisopropyl azodicarboxylate and diethyl azodicarboxylate;
[0050] L-3 is deprotected under hydrochloric acid or trifluoroacetic acid to obtain L-4; the deprotection reaction is carried out by conventional methods in the art. Compound L-3 is dissolved in an organic solvent, and hydrochloric acid / dioxane or hydrochloric acid / ethanol or hydrochloric acid / dichloromethane solution or trifluoroacetic acid is added, and the reaction is carried out at room temperature for 1-24 hours. The organic solvent is any solvent that has no adverse effect on the reaction, preferably dichloromethane (DCM), dioxane, methanol, etc.
[0051] L-4 and different fragments are reacted by nucleophilic substitution to obtain L-5; the nucleophilic substitution reaction is carried out by conventional methods in the art. Compound L-4 and different organic building block fragments are dissolved in an organic solvent, an alkaline reagent is added, and the reaction is carried out at 0-140° C. for 1-24 hours. The solvent can be any solvent that has no adverse effect on the reaction, preferably acetonitrile, DMF, etc.
[0052] L-5 is hydrolyzed under alkaline conditions to obtain L-6; the hydrolysis reaction is carried out by a conventional method in the art, compound I is dissolved in a mixed solvent of an organic solvent and water, an alkaline reagent is added, and the reaction is carried out at room temperature to 100° C. for 1-24 hours. The organic solvent is any solvent that has no adverse effect on the reaction, preferably dioxane, methanol, tetrahydrofuran, etc.
[0053] Method 2: Preparation of the compound represented by the general formula L-14
[0054]
[0055] wherein R1, R2, R3, R4, R5, m, n, and o are as defined above;
[0056] Compound L-7 is reacted with methyl bromoacetate to obtain L-8 by a nucleophilic substitution reaction; the nucleophilic substitution reaction is carried out by a conventional method in the art. L-7 is dissolved in an organic solvent, an alkaline reagent is added, and then methyl bromoacetate is added, and the reaction is carried out at 0-140° C. for 1-24 hours. The solvent can be any solvent that has no adverse effect on the reaction, preferably acetonitrile, DMF, etc.
[0057] L-8 is reduced with hydrogen under the catalysis of Pd / C to obtain L-9; the reduction reaction is carried out by a conventional method in the art. L-8 is dissolved in an organic solvent, an appropriate amount of Pd / C is added, and the reaction is carried out at room temperature to 40° C. for 1-24 hours in a hydrogen environment. The solvent can be any solvent that has no adverse effect on the reaction, preferably methanol, ethyl acetate, etc.
[0058] L-9 is reacted with different linker fragments L-10 to obtain L-11 through Mitsunobu reaction; the Mitsunobu reaction is carried out by conventional methods in the art. Lc and the corresponding alcohol linker fragment are dissolved in an organic solvent, triphenylphosphine and azo reagent are added, and the reaction is carried out at 0-60°C for 1-24 hours. The solvent can use any solvent that has no adverse effect on the reaction, preferably dichloromethane, tetrahydrofuran, etc. The azo reagent is diisopropyl azodicarboxylate, diethyl azodicarboxylate, N,N,N',N'-tetramethylazodicarbonamide, etc., preferably diisopropyl azodicarboxylate and diethyl azodicarboxylate.
[0059] L-11 is deprotected under hydrochloric acid or trifluoroacetic acid to obtain L-12; the deprotection reaction is carried out by conventional methods in the art. Compound L-11 is dissolved in an organic solvent, and hydrochloric acid / dioxane or hydrochloric acid / ethanol or hydrochloric acid / dichloromethane solution or trifluoroacetic acid is added, and the reaction is carried out at room temperature for 1-24 hours. The organic solvent is any solvent that has no adverse effect on the reaction, preferably dichloromethane (DCM), dioxane, methanol, etc.
[0060] L-12 and different fragments are reacted by nucleophilic substitution to obtain L-13; the nucleophilic substitution reaction is carried out by conventional methods in the art. Compound L-12 and different organic building block fragments are dissolved in an organic solvent, an alkaline reagent is added, and the reaction is carried out at 0-140° C. for 1-24 hours. The solvent can be any solvent that has no adverse effect on the reaction, preferably acetonitrile, DMF, etc.
[0061] L-13 is hydrolyzed under alkaline conditions to obtain L-14; the hydrolysis reaction is carried out by a conventional method in the art, compound L-13 is dissolved in a mixed solvent of an organic solvent and water, an alkaline reagent is added, and the reaction is carried out at room temperature to 100° C. for 1-24 hours. The organic solvent is any solvent that has no adverse effect on the reaction, preferably dioxane, methanol, tetrahydrofuran, etc.
[0062] Method 3: Preparation of the compound represented by the general formula L-14
[0063]
[0064] wherein R1, R2, R3, R4, m, n, and o are as defined above;
[0065] Except for replacing L-1 with L-15, the other preparation methods refer to method 1.
[0066] Method 4: Preparation of the compound represented by the general formula L-26
[0067]
[0068] wherein R1, R2, R3, R4, R5, m, n, and o are as defined above;
[0069] Compound L-21 is reacted with different linker fragments L-22 to obtain L-23 by Buchwald reaction; the Buchwald reaction is carried out by conventional methods in the art. Compounds L-21 and L-22 are dissolved in an organic solvent, and an alkaline agent, a metal catalyst, and a ligand are added, and the reaction is carried out at 60-140° C. for 1-24 hours. The solvent can use any solvent that has no adverse effect on the reaction, preferably 1,4-dioxane, N,N-dimethylformamide (DMF), etc. The alkaline agent includes, but is not limited to, cesium carbonate, potassium carbonate, potassium phosphate, potassium fluoride, triethylamine (TEA), N,N-diisopropylethylamine, etc. (DIPEA), preferably cesium carbonate, potassium phosphate. The metal catalyst includes, but is not limited to, cuprous iodide, tris(dibenzylideneacetone)dipalladium, palladium acetate, etc., preferably cuprous iodide, tris(dibenzylideneacetone)dipalladium. The ligand includes, but is not limited to, triphenylphosphine, 2-dicyclohexylphospho-2,4,6-triisopropylbiphenyl, and the like, preferably 2-dicyclohexylphospho-2,4,6-triisopropylbiphenyl.
[0070] L-23 is deprotected under hydrochloric acid or trifluoroacetic acid to obtain L-24; the deprotection reaction is carried out by conventional methods in the art. Compound L2-3 is dissolved in an organic solvent, and hydrochloric acid / dioxane or hydrochloric acid / ethanol or hydrochloric acid / dichloromethane solution or trifluoroacetic acid is added, and the reaction is carried out at room temperature for 1-24 hours. The organic solvent is any solvent that has no adverse effect on the reaction, preferably dichloromethane (DCM), dioxane, methanol, etc.
[0071] L-24 reacts with different fragments to obtain L-25 through nucleophilic substitution reaction; the nucleophilic substitution reaction is carried out by conventional methods in the art. Compound L-24 and different organic building block fragments are dissolved in an organic solvent, an alkaline reagent is added, and the reaction is carried out at 0-140° C. for 1-24 hours. The solvent can be any solvent that has no adverse effect on the reaction, preferably acetonitrile, DMF, etc.
[0072] L-25 is hydrolyzed under alkaline conditions to obtain L-26; the hydrolysis reaction is carried out by conventional methods in the art. Compound L-25 is dissolved in a mixed solvent of an organic solvent and water, an alkaline reagent is added, and the reaction is carried out at room temperature to 100° C. for 1-24 hours. The organic solvent is any solvent that has no adverse effect on the reaction, preferably dioxane, methanol, tetrahydrofuran, etc.
[0073] Method 5: Preparation of the compound represented by the general formula L-14
[0074]
[0075] wherein R1, R2, R3, R4, m, n, and o are as defined above;
[0076] L-27 reacts with trifluoromethanesulfonic anhydride under alkaline conditions to obtain L-28; the reaction is carried out by a conventional method in the art. Compound L-27 is dissolved in an organic solvent, an alkaline reagent is added, and then trifluoromethanesulfonic anhydride is added dropwise at 0°C, and the reaction is carried out in an ice bath for 1-24 hours. The mailing solvent is any solvent that has no adverse effect on the other party, preferably dichloromethane, tetrahydrofuran, etc.
[0077] Except for using L-28 to replace L-21, the other preparation methods refer to method 4.
[0078] Method 6:
[0079]
[0080] wherein R1, R2, R3, R4, R5, m, n, and o are as defined above;
[0081] Except for replacing L-27 with L-34, the other preparation methods refer to method 5.
[0082] According to one embodiment of the present invention, there is provided a pharmaceutical composition comprising the compound represented by the general formula I as described above, a solvent compound, a hydrate and a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0083] According to one embodiment of the present invention, the pharmaceutical composition further comprises other known drugs for treating type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), gallstones, inflammatory bowel disease, and neurodegenerative diseases, and the other drugs include DPP4 inhibitors.
[0084] According to one embodiment of the present invention, the other known drugs include sitagliptin, etc.;
[0085] According to one embodiment of the present invention, it provides the use of the above-mentioned compound, solvate, hydrate and pharmaceutically acceptable salt thereof in the preparation of a drug for preventing or treating a disease mediated by GPR40 and SSTR5;
[0086] According to one embodiment of the present invention, it provides the use of the above-mentioned pharmaceutical composition in preventing or treating diseases mediated by GPR40 and SSTR5;
[0087] Wherein, the diseases mediated by GPR40 and SSTR5 are type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), inflammatory bowel disease, neurodegenerative diseases, etc.;
[0088] Beneficial Effects
[0089] The compounds according to the present invention can be effectively used to prevent or treat diseases mediated by GPR40 and SSTR5, more specifically can be used to prevent or treat type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), gallstones, inflammatory bowel disease, neurodegenerative diseases. DETAILED DESCRIPTION
[0090] definition
[0091] Unless otherwise specified, the terms used in this invention have the following definitions:
[0092] The term "substituted" as used herein means replacement by one or more groups. When multiple groups are selected from the same series of candidate substituents, they may be the same or different.
[0093] The "alkyl" mentioned in the present invention refers to a saturated straight-chain or branched alkyl group with a specific number of atoms, and specifically includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, etc. The "C1-3 alkyl" refers to a saturated straight-chain or branched alkyl group with 1 to 3 carbon atoms, and specifically includes, but is not limited to, methyl, ethyl, propyl, isopropyl, etc.
[0094] The "cycloalkyl" mentioned in the present invention represents a non-aromatic, saturated, cyclic aliphatic hydrocarbon group having 3 to 6 ring atoms. Representative examples include but are not limited to: cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
[0095] The "alkoxy" described in the present invention refers to all straight-chain or branched isomers with a specific number of carbon atoms, and specific examples include but are not limited to methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, and the like.
[0096] The "halogen" refers to fluorine, chlorine, bromine or iodine.
[0097] In the present invention, if the substitution on the alkyl or cycloalkyl group is not specified to occur on a specific carbon atom, it means that it can occur on any carbon atom that has not reached saturation with the number of substituents. When multiple substituents are selected from the same series, they can be the same or different.
[0098] In the present invention, substitution on a benzene ring, aromatic heterocycle or heterocycle, if not specified to occur on a specific atom, means that it can occur at any position that is not substituted by other atoms other than hydrogen and. When multiple substituents are selected from the same series, they can be the same or different.
[0099] "Pharmaceutically acceptable salt" means that the compound of formula (I) retains the desired biological activity and has minimal toxic side effects. The pharmaceutically acceptable salt can be obtained directly during the preparation and purification of the compound, or indirectly by reacting the free acid or free base of the compound with another suitable base or acid.
[0100] The term "solvate" is used herein to describe a molecular complex comprising a compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules (eg, ethanol). The term "hydrate" is employed when the solvent is water.
[0101] How to use
[0102] When used for treatment, the compounds of the present invention are usually administered in the form of a standard pharmaceutical composition, which contains one or more compounds of the general formula (I) in an effective therapeutic dose, and pharmaceutically acceptable excipients. The pharmaceutically acceptable excipients are pharmaceutically acceptable carriers, excipients or sustained-release agents, etc.
[0103] The compound and pharmaceutical composition provided by the present invention can be in various forms, such as tablets, capsules, powders, syrups, solutions, suspensions and aerosols, and can be present in suitable solid or liquid carriers or diluents. The pharmaceutical composition of the present invention can also be stored in suitable sterilizing apparatus for injection or instillation. The pharmaceutical composition can also contain odorants, flavoring agents, etc.
[0104] In the present invention, the pharmaceutical composition contains a safe and effective amount (such as 0.1-99.9 parts by weight, preferably 1-90 parts by weight) of a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof; and the remainder of pharmaceutically acceptable excipients, wherein the total weight of the composition is 100 parts by weight. Alternatively, the pharmaceutical composition of the present invention contains 0.1-99.9% by weight, preferably 1-90% by weight of a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof; and the remainder of pharmaceutically acceptable excipients, wherein the total weight of the composition is 100% by weight.
[0105] The preferred ratio of the compound represented by general formula (I) to the pharmaceutically acceptable carrier, excipient or sustained-release agent is that the compound represented by general formula (I) as the active ingredient accounts for more than 60% of the total weight, and the remaining part accounts for 0-40% of the total weight, and the amount of the remaining part is preferably 1-20%, and most preferably 1-10%.
[0106] The compound represented by the general formula (I) or the pharmaceutical composition comprising the compound represented by the general formula (I) can be used clinically in mammals, including humans and animals, and the administration route can include oral administration, nasal inhalation, transdermal absorption, pulmonary administration or gastrointestinal tract, etc. The preferred administration route is oral administration. It is preferably a unit dosage form, and each dose contains 0.01 mg-300 mg of the active ingredient, preferably 0.5 mg-200 mg, which is taken once or in divided doses. Regardless of the method of administration, the optimal dose for an individual should be determined according to the specific treatment. Usually, it is started with a small dose and gradually increased until the most suitable dose is found.
[0107] The pharmaceutical composition of the present invention can be administered orally as well as intravenously, intramuscularly or subcutaneously. From the standpoint of ease of preparation and administration, the preferred pharmaceutical composition is a solid composition, especially tablets and solid-filled or liquid-filled capsules. Oral administration of the pharmaceutical composition is preferred.
[0108] Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, etc., while liquid carriers include sterile water, polyethylene glycol, nonionic surfactants and edible oils (such as corn oil, peanut oil and sesame oil), etc., as long as they are suitable for the characteristics of the active ingredient and the specific administration method required. Adjuvants commonly used in the preparation of pharmaceutical compositions may also be advantageously included, such as flavoring agents, pigments, preservatives and antioxidants such as vitamin E, vitamin C, BHT and BHA.
[0109] Injectable preparations include, but are not limited to, sterile, injectable, aqueous, oily solutions, suspensions, emulsions, and the like. These preparations may also be formulated with suitable parenteral diluents, dispersants, wetting agents, suspending agents, and the like. Such injectable preparations may be sterilized by filtration in a filter that retains bacteria. These preparations may also be formulated with a bactericide that is dissolved or dispersed in an injectable medium or by other methods known in the art.
[0110] The compounds of the present invention can be used in combination with DPP4 inhibitors to treat, prevent or improve diseases for which the compounds of the present invention or other drugs may be effective, wherein the combination of DPP4 inhibitors is safer or more effective than the use of any one drug alone. DPP4 inhibitors can be administered simultaneously with the compounds of the present invention or before or after administration by commonly used routes of administration and dosages. When the compounds of the present invention are used simultaneously with the DPP4 inhibitors, a pharmaceutical composition comprising the DPP4 inhibitor and the compounds of the present invention in a unit dosage form is preferred. However, combination therapy may also include a therapy in which the compounds of the formula described herein and the DPP4 inhibitors are administered in different overlapping schemes. When the DPP4 inhibitors are used in combination, the compounds of the present invention and the DPP4 inhibitors can be used in a lower dosage than when used alone.
[0111] Preparation Example
[0112] The present invention will be further described below with reference to examples. It should be particularly noted that these examples are only used to illustrate the present invention and are not intended to limit the present invention in any way. All parameters and other descriptions in the examples are based on mass unless otherwise specified. The fillers used for column chromatography separation are all silica gel unless otherwise specified. The experimental methods in the following examples that do not specify specific conditions are usually carried out under conventional conditions or under conditions recommended by the manufacturer.
[0113] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein may be applied to the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only.
[0114] Preparation Example
[0115] Example 1
[0116] Preparation of 3-(3-((1-((2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)azetidin-3-yl)methoxy)phenyl)propanoic acid, trifluoroacetate
[0117]
[0118] Step 1: Preparation of 4-(chloromethyl)-2,6-diethoxy-4'-fluoro-1,1'-biphenyl (A1a)
[0119]
[0120] Preparation method reference: ACS Med. Chem. Lett. 2018, 9, 11, 1082–1087
[0121] 1 H NMR (500 MHz, CHLOROFORM-d) δ 7.39–7.31 (m, 2H), 7.12–7.05 (m, 2H), 6.68 (s, 2H), 4.61 (s, 2H), 4.01 (q, J = 7.0 Hz, 4H), 1.28 (t, J = 6.9 Hz, 6H).
[0122] MS (ESI): m / z 309.2 [M+H] + .
[0123] Step 2: Preparation of tert-butyl 3-((3-(3-methoxy-3-oxopropyl)phenoxy)methyl)azetidine-1-carboxylate (A1b)
[0124]
[0125] Dissolve methyl 3-(3-hydroxyphenyl)propionate (1 eq), tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate (1 eq), and triphenylphosphine (1.5 eq) in ultra-dry dichloromethane, replace nitrogen, place in an ice bath, slowly dropwise add diisopropyl azodicarboxylate (DIAD) (2 eq), react in nitrogen for 5 h, confirm the reaction is complete by thin layer chromatography, mix the filtrate with silica gel, and purify by flash silica gel column chromatography (DCM / MeOH=50:1 to 20:1) to obtain a white oil A1b. MS (ESI): m / z 350.2 [M+H] + .
[0126] 1H NMR (500MHz, chloroform-d) δ7.23(td,J=7.3,1.7Hz,1H),6.86–6.81(m,1H),6.77(dd,J=8.2,1.9Hz,2H),4.13–4.07(m,4H) ,3.81(dd,J=8.8,5.2Hz,2H),3.70(s,3H),2.96(dt,J=15.8,7.3Hz,3H),2.65(dd,J=8.4,7.2Hz,2H),1.47(s,9H).
[0127] Step 3: Preparation of methyl 3-(3-(azetidin-3-ylmethoxy)phenyl)propanoate, hydrochloride (A1c)
[0128]
[0129] Dissolve A1b in dichloromethane, add 3-5mL of hydrochloric acid-dioxane solution (4N), react at room temperature for 2 hours, and confirm the reaction is complete by thin layer chromatography. Filter the reaction solution to obtain a solid, which is the product A1c, and no purification is required. MS (ESI): m / z 250.1 [M+H] + .
[0130] Step 4: Preparation of methyl 3-(3-((1-((2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)azetidin-3-yl)methoxy)phenyl)propanoate (A1d)
[0131]
[0132] A1c (1 eq) was dissolved in acetonitrile, potassium carbonate (2 eq) was added, and the mixture was stirred at room temperature for 10 minutes. A1a (1 eq) was then added and stirred at 60°C for 5 hours. The reaction was confirmed to be complete by thin layer chromatography. The filtrate was mixed with silica gel and purified by flash silica gel column chromatography (DCM / MeOH = 50:1 to 20:1) to obtain white oil A1d. MS (ESI): m / z 523.3 [M+H] + .
[0133] 1H NMR (500MHz, chloroform-d) δ7.35–7.30(m,2H),7.21(td,J=7.5,1.3Hz,1H),7.08–7.01(m,2H),6.83–6.74(m,3H),6.59(s,2H),4.08(d,J=6.1Hz,2H),3. 97(q,J=6.9Hz,4H),3.72(d,J=10.9Hz,4H),3.67(s,3H),3.04(s,1H),2.93(t,J=7.9Hz,2H),2.63(dd,J=8.5,7.3Hz,2H),1.24(t,J=7.0Hz,8H).
[0134] Step 5: Preparation of 3-(3-((1-((2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)azetidin-3-yl)methoxy)phenyl)propanoic acid, trifluoroacetate (A1e)
[0135]
[0136] A1d (1 eq) was dissolved in a mixed solvent of 1,4-dioxane and water (volume ratio = 4:1), and lithium hydroxide monohydrate (2 eq) was added. The reaction was allowed to react at 50°C for 12 hours. Thin layer chromatography confirmed that the reaction was complete. The reaction solution was concentrated and evaporated to dryness, and trifluoroacetate A1e was obtained by semi-preparative liquid phase purification. MS (ESI): m / z 508.2 [M+H] + .
[0137] 1 H NMR (500MHz, chloroform-d) δ7.32–7.28(m,2H),7.21(t,J=7.8Hz,1H),7.09–7.01(m ,2H),6.89–6.83(m,2H),6.75(dd,J=8.2,2.5Hz,1H),6.67(s,2H),4.22(s, 4H),4.04(d,J=4.3Hz,2H),3.94(q,J=7.0Hz,4H),3.91(d,J=11.0Hz,2H),3 .36(s,1H),2.93(t,J=7.3Hz,2H),2.69–2.60(m,2H),1.23(t,J=7.0Hz,6H).
[0138] Example 2
[0139] Preparation of 3-(3-((1-((2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)piperidin-4-yl)methoxy)phenyl)propanoic acid, trifluoroacetate
[0140]
[0141] Except that tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate was used instead of tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate, the other preparation methods were the same as those in Example 1. MS (ESI): m / z 536.3 [M+H] + .
[0142] 1 H NMR (500MHz, chloroform-d) δ7.37–7.31(m,2H),7.20(t,J=7.8Hz,1H),7.13–7.05 (m,2H),6.86–6.78(m,2H),6.73(d,J=8.7Hz,3H),4.17(s,2H),3.98(q,J =7.0Hz, 4H), 3.91 (d, J = 5.7Hz, 2H), 3.73 (d, J = 11.9Hz, 2H), 2.96 (t, J = 7. 3Hz,2H),2.67(t,J=8.4Hz,3H),2.11–1.89(m,5H),1.27(t,J=6.9Hz,7H).
[0143] Example 3
[0144] Preparation of 3-(3-((1-((2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)piperidin-4-yl)oxy)phenyl)propanoic acid, trifluoroacetate
[0145]
[0146] Except that tert-butyl 4-hydroxypiperidine-1-carboxylate was used instead of tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate, the other preparation methods were the same as those in Example 1. MS (ESI): m / z 522.3 [M+H] + .
[0147] 1H NMR (500MHz, chloroform-d) δ7.33–7.28(m,2H),7.22(t,J=7.9Hz,1H),7.09–7.02(m,2H),6.84(d,J =7.6Hz,1H),6.79(t,J=2.0Hz,1H),6.75–6.69(m,3H),4.67(s,1H),4.15(s,2H),3.96(qd,J =6.9,1.9Hz,4H),3.47(d,J=11.4Hz,2H),3.08(s,2H),2.93(t,J=7.5Hz,2H),2.64(dt,J=15 .6,7.5Hz,2H),2.36(t,J=13.8Hz,2H),2.14(d,J=14.7Hz,2H),1.24(td,J=6.9,1.8Hz,6H).
[0148] Example 4
[0149] Preparation of 3-(3-((1-((2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)piperidin-4-yl)amino)phenyl)propionic acid, trifluoroacetate
[0150]
[0151] Step 1: Preparation of tert-butyl 4-((3-(3-methoxy-3-oxopropyl)phenyl)amino)piperidine-1-carboxylate (A4a)
[0152]
[0153] 4-aminopiperidine-1-carboxylic acid tert-butyl ester (1 eq), m-bromophenylpropionic acid methyl ester (1.5 eq), potassium phosphate (3 eq), Pd(dba) (0.05 eq), and Xantphos ligand (0.1 eq) were dissolved in 1,4-dioxane, and the mixture was sealed and reacted at 100°C for 3 hours after nitrogen replacement. The reaction was confirmed to be complete by thin layer chromatography. The reaction solution was cooled to room temperature, the solid was removed by filtration, and the filtrate was mixed with silica gel for flash silica gel column chromatography (DCM / MeOH=50:1 to 20:1) to obtain a white oil A4a with a yield of 1.5%. MS (ESI): m / z 363.2 [M+H] + .
[0154] 1H NMR (500MHz, chloroform-d) δ7.09(t,J=7.6Hz,1H),6.53(d,J=7.5Hz,1H),6.44(d,J=7.9Hz,2H),4.08(d,J=36.5Hz,2H),3.67(s,3H),3.42(td,J= 9.9, 4.9Hz, 1H), 2.91 (d, J = 12.9Hz, 1H), 2.86 (t, J = 8.0Hz, 2H), 2.61 (t, J = 8.0Hz, 2H), 2.08–1.97 (m, 2H), 1.46 (s, 9H), 1.37–1.22 (m, 4H).
[0155] Step 2: Preparation of methyl 3-(3-(piperidin-4-ylamino)phenyl)propanoate, hydrochloride (A4b)
[0156]
[0157] A4a was dissolved in dichloromethane, and 3-5 mL of hydrochloric acid-dioxane solution (4N) was added. The reaction was allowed to react at room temperature for 2 hours. Thin layer chromatography confirmed that the reaction was complete. The reaction solution was concentrated to obtain the product A4b, which did not require purification. MS (ESI): m / z 263.1 [M+H] + .
[0158] Step 3: Preparation of methyl 3-(3-((1-((2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)piperidin-4-yl)amino)phenyl)propanoate (A4c)
[0159]
[0160] A4b (1 eq) was dissolved in acetonitrile, potassium carbonate (2 eq) was added, and the mixture was stirred at room temperature for 10 minutes. A1a (1 eq) was then added and stirred at 60°C for 5 hours. The reaction was confirmed to be complete by thin layer chromatography. The filtrate was mixed with silica gel and purified by flash silica gel column chromatography (DCM / MeOH = 50:1 to 20:1) to obtain colorless oil A4c. MS (ESI): m / z 535.3 [M+H] + .
[0161] 1H NMR (500MHz, DMSO-d6) δ7.31–7.25(m,2H),7.18–7.11(m,2H),6.94(t,J=7.7Hz,1H),6.66(s, 2H),6.45–6.33(m,3H),5.42–5.24(m,1H),3.94(q,J=6.9Hz,4H),3.67(s,3H),3.47(s,2H),3. 20(s,1H),2.84(dt,J=11.9,3.8Hz,2H),2.67(t,J=7.7Hz,2H),2.45(t,J=7.7Hz,2H),2.13(t d,J=11.7,2.5Hz,2H),1.96–1.84(m,2H),1.43(dd,J=12.2,9.0Hz,2H),1.12(t,J=6.9Hz,6H).
[0162] Step 4: Preparation of 3-(3-((1-((2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)piperidin-4-yl)amino)phenyl)propanoic acid, trifluoroacetate (A4d)
[0163]
[0164] A4c (1 eq) was dissolved in a mixed solvent of 1,4-dioxane and water (volume ratio = 4:1), and lithium hydroxide monohydrate (2 eq) was added. The reaction was allowed to react at 50°C for 12 hours. Thin layer chromatography confirmed that the reaction was complete. The reaction solution was concentrated and evaporated to dryness, and trifluoroacetate A4d was obtained by semi-preparative liquid phase purification. MS (ESI): m / z 521.3 [M+H] + .
[0165] 1 H NMR(500MHz,DMSO-d6)δ7.31–7.25(m,2H),7.18–7.11(m,2H),6.94(t,J=7.7Hz,1H),6.66 (s,2H),6.45–6.33(m,3H),5.42–5.24(m,1H),3.94(q,J=6.9Hz,4H),3.47(s,2H),3.20(s, 1H),2.84(dt,J=11.9,3.8Hz,2H),2.67(t,J=7.7Hz,2H),2.45(t,J=7.7Hz,2H),2.11(td,J =11.7,2.5Hz,2H),1.98–1.86(m,2H),1.41(dd,J=12.2,9.0Hz,2H),1.15(t,J=6.9Hz,6H).
[0166] Example 5
[0167] Preparation of (S)-3-cyclopropyl-3-(3-((1-(2-cyclopropyl-5-ethoxybenzyl)azetidin-3-yl)methoxy)phenyl)propanoic acid, trifluoroacetate
[0168]
[0169] Step 1: Preparation of ethyl 2-bromo-5-ethoxybenzoate (A5a)
[0170]
[0171] 2-Bromo-5-hydroxybenzoic acid (1 eq) was dissolved in acetonitrile, potassium carbonate (3 eq) was then added, and the mixture was stirred at room temperature for 10 minutes. Ethyl iodide (2.5 eq) was added dropwise, and the reaction mixture was heated to 70°C. After the reaction was completed by TLC monitoring, the solid was removed by filtration after cooling. The filtrate was concentrated and purified by flash chromatography (PE / EA = 100:1 to 10:1) to obtain colorless liquid A5a. MS (ESI): m / z 273.1 [M+H] + .
[0172] Step 2: Preparation of ethyl 2-cyclopropyl-5-ethoxybenzoate (A5b)
[0173]
[0174] A5a, cesium carbonate (2 eq), cyclopropylboronic acid (1.2 eq), and Pd(dppf)Cl2 (0.05 eq) were dissolved in dioxane solvent in a sealed tube and reacted at 90°C for 3 h under nitrogen. After the reaction was complete as monitored by thin layer chromatography, the filtrate was concentrated and purified by flash chromatography (PE / EA=100:1 to 10:1) to obtain colorless liquid A5b. MS (ESI): m / z 235.1 [M+H] + .
[0175] Step 3: Preparation of (2-cyclopropyl-5-ethoxyphenyl)methanol (A5c)
[0176]
[0177] A5b was dissolved in ultra-dry tetrahydrofuran solution, placed in an ice bath, and lithium aluminum tetrahydride solution (2.5M, 1eq) was slowly added dropwise. The reaction was allowed to proceed in an ice bath for 30 minutes. The reaction was monitored to be complete by thin layer chromatography. A 0.5 mol NaOH solution was added to quench the reaction. The solid part was removed by filtration and concentrated to obtain a colorless liquid A5c. The product thus obtained did not require further purification. MS (ESI): m / z 193.1 [M+H] + .
[0178] Step 4: Preparation of 2-(chloromethyl)-1-cyclopropyl-4-ethoxybenzene (A5d)
[0179]
[0180] A5c was dissolved in dichloromethane, placed in an ice bath, and thionyl chloride (2 eq) was slowly added dropwise, and the mixture was reacted in an ice bath for 2 h. The reaction was complete after monitoring by thin layer chromatography. The reaction solution was concentrated to obtain a light yellow liquid (A5d). The product thus obtained did not require further purification. MS (ESI): m / z 211.1 [M+H] + .
[0181] Step 5: Preparation of (S)-3-cyclopropyl-3-(3-((1-(2-cyclopropyl-5-ethoxybenzyl)azetidin-3-yl)methoxy)phenyl)propanoic acid, trifluoroacetate (A5e)
[0182]
[0183] Except that A5d was used instead of A1a, and (S)-3-cyclopropyl-3-(3-hydroxyphenyl)propionic acid methyl ester was used instead of 3-(3-hydroxyphenyl)propionic acid methyl ester. The other preparation methods were the same as those in Example 1. MS (ESI): m / z 450.3 [M+H] + .
[0184] 1 H NMR (500MHz, DMSO-d6) δ7.11(t,J=7.8Hz,1H),6.85(d,J=8.4Hz,1H),6.82(d,J=2.8Hz,1H),6.81–6.76(m,2H),6.67(ddd ,J=18.0,8.3,2.7Hz,2H),4.08(d,J=6.9Hz,2H),3.95(q,J=6.9Hz,2H),3.69(s,2H),3.34(m,1H),3.04(dd,J=7.1,5.7Hz, 2H),2.82(q,J=6.6Hz,1H),2.39–2.19(m,3H),2.03–1.84(m,1H),1.29(t,J=7.0Hz,3H),1.23(d,J=2.8Hz,1H),0.94–0.8 7(m,1H),0.86–0.81(m,2H),0.55–0.47(m,2H),0.44–0.36(m,1H),0.24(tdd,J=10.6,5.4,3.3Hz,2H),0.10–0.00(m,1H).
[0185] Example 6
[0186] Preparation of 2-(carboxymethoxy)-5-((1-(2-cyclopropyl-5-ethoxybenzyl)piperidin-4-yl)methoxybenzoic acid, trifluoroacetate
[0187]
[0188] Step 1: Preparation of methyl 5-(benzyloxy)-2-(2-methoxy-2-oxoethoxy)benzoate (A6a)
[0189]
[0190] Dissolve methyl 5-(benzyloxy)-2-hydroxybenzoate (1 eq) in acetonitrile, add potassium carbonate (2 eq), stir at room temperature for 10 minutes, then slowly dropwise add methyl bromoacetate (1.5 eq), stir at 70°C for 2 hours, monitor the reaction by thin layer chromatography, concentrate the filtrate and purify by flash chromatography (PE / EA=100:1 to 8:1) to obtain colorless liquid A6a. MS (ESI): m / z 331.1 [M+H] + .
[0191] Step 2: Preparation of methyl 5-hydroxy-2-(2-methoxy-2-oxoethoxy)benzoate (A6b)
[0192] A6a was dissolved in methanol, and an appropriate amount of Pd / C was added. The reaction was carried out at room temperature for 1 h under hydrogen. After the reaction was completed by TLC monitoring, the solid was filtered out and the filtrate was concentrated to obtain a colorless liquid A6b. The product obtained in this way did not need further purification. MS (ESI): m / z 241.1 [M+H] + .
[0193] Step 3: Preparation of 2-(carboxymethoxy)-5-((1-(2-cyclopropyl-5-ethoxybenzyl)piperidin-4-yl)methoxybenzoic acid, trifluoroacetate (A6c)
[0194]
[0195] The preparation method is the same as Example 1 except that A5d is used instead of A1a, tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate is used instead of tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate, and A6b is used instead of methyl 3-(3-hydroxyphenyl)propionate. MS (ESI): m / z 484.3 [M+H] + .
[0196] 1H NMR (500MHz, DMSO-d6) δ7.26(s,1H),7.16(d,J=8.9Hz,1H),6.97(d,J=7.4Hz,2H),6.83(s,1H),6.68(s,1H),4.46(s,2H),3.99(q,J=7.3Hz,2H) ,2.91(d,J=7.4Hz,4H),2.04–1.92(m,4H),1.53–1.38(m,2H),1.30(t,J =7.0Hz,3H),1.16(s,2H),0.89(s,1H),0.87–0.82(m,3H),0.56(s,2H).
[0197] Example 7
[0198] Preparation of 2-(carboxymethoxy)-4-((1-(2-cyclopropyl-5-ethoxybenzyl)piperidin-4-yl)methoxybenzoic acid, trifluoroacetate
[0199]
[0200] Except that 4-(benzyloxy)-2-hydroxybenzoic acid methyl ester was used instead of 5-(benzyloxy)-2-hydroxybenzoic acid methyl ester, the rest of the preparation method was the same as Example 6. MS (ESI): m / z 484.3 [M+H] + .
[0201] 1 H NMR (500MHz, DMSO-d6) δ7.63(s,1H),7.30–6.81(m,3H),6.78–6.50(m,2H),4.71(s,2H),4.35(s,2H),3.95(d,J=50. 3Hz,3H),3.03(s,3H),1.98(d,J=49.9Hz,4H),1.68–1.47(m,4H),1.28(t,J=20.4Hz,3H),0.92(s,2H),0.60(s,2H).
[0202] Example 8
[0203] Preparation of 2-(6-((1-(2-cyclopropyl-5-ethoxybenzyl)piperidin-4-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid, trifluoroacetate
[0204]
[0205] Except that methyl 2-(6-hydroxy-2,3-dihydrobenzofuran-3-yl)acetate was used instead of methyl (S)-3-cyclopropyl-3-(3-hydroxyphenyl)propionate, the other preparation methods were the same as those in Example 5. MS (ESI): m / z 466.3 [M+H] + .
[0206] 1 H NMR (500MHz, DMSO-d6) δ7.22(s,1H),7.08(d,J=8.2Hz,1H),6.88(d,J=9.0Hz,2H),6.69(s,1H),6.41–6.34(m ,2H),5.32(t,J=5.0Hz,1H),4.67(t,J=9.0Hz,1H),4.18(dd,J=9.1,6.7Hz,1H),3.96(q,J=6.8Hz,2H),3.76( d,J=5.9Hz,2H),3.71–3.62(m,1H),3.16(d,J=5.0Hz,1H),2.92(q,J=7.3Hz,4H),2.69(dd,J=16.7,5.6Hz,1H ),2.54(s,1H),1.73(s,4H),1.49–1.42(m,2H),1.31–1.27(m,3H),0.87–0.83(m,2H),0.51(d,J=5.0Hz,2H).
[0207] Example 9
[0208] Preparation of (S)-3-cyclopropyl-3-(3-((1-(2-cyclopropyl-5-(trifluoromethyl)benzyl)piperidin-4-yl)amino)phenyl)propanoic acid, trifluoroacetate
[0209]
[0210] Step 1: Preparation of 2-(chloromethyl)-1-cyclopropyl-4-(trifluoromethyl)benzene (A9a)
[0211]
[0212] Except for using 2-bromo-5-(trifluoromethyl)benzoic acid instead of 2-bromo-5-hydroxybenzoic acid, the other preparation methods refer to the preparation of A5a. MS (ESI): m / z 235.1 [M+H] + .
[0213] Step 2: Preparation of (S)-3-cyclopropyl-3-(3-((1-(2-cyclopropyl-5-(trifluoromethyl)benzyl)piperidin-4-yl)amino)phenyl)propanoic acid, trifluoroacetate (14b)
[0214]
[0215] Except that A9a was used instead of A1a, and (S)-3-cyclopropyl-3-(3-hydroxyphenyl)propionic acid methyl ester was used instead of 3-(3-hydroxyphenyl)propionic acid methyl ester, the other preparation methods were the same as those in Example 5. MS (ESI): m / z 487.3 [M+H] + .
[0216] 1 H NMR (500MHz, DMSO-d6) δ9.53(s,1H),7.92(d,J=6.3Hz,1H),7.70(d,J=8.3Hz,1H),7.33–7.20(m,2H),6.99(t,J=7 .7Hz,1H),6.44(q,J=8.7Hz,2H),4.59(s,1H),3.29(d,J=13.4Hz,4H),2.75–2.52(m,2H),2.40–1.84(m,5H),1.64– 1.40(m,2H),1.33–1.17(m,2H),1.14–1.09(m,2H),0.94(tq,J=8.6,4.2,3.8Hz,1H),0.83(dd,J=9.1,4.1Hz,2H), 0.47(tt,J=9.0,4.5Hz,1H), 0.30(tt,J=9.1,4.8Hz,1H), 0.20(dq,J=9.6,4.8Hz,1H), 0.08(dq,J=9.6,5.2Hz,1H).
[0217] Pharmacological Examples:
[0218] Pharmacological Examples:
[0219] 1. In vitro SSTR5 antagonistic activity test of the present invention:
[0220] 1.1 Test method: calcium flow detection method
[0221] 1) Experimental principle: After the receptor binds to the ligand and is activated, it can cause the activation of Gα16 protein, which in turn activates phospholipase C (PLC) to produce IP3 and DAG. IP3 can bind to the IP3 receptors on the endoplasmic reticulum and mitochondria in the cell, thereby causing the release of intracellular calcium. Therefore, measuring the changes in intracellular calcium can be used as a method to detect the activation state of hSSTR5 and GPR40. Fluo-4 / AM is a calcium fluorescent probe indicator used to measure calcium ions. As a non-polar, lipid-soluble compound, after entering the cell, under the action of cellular lipase, the AM group dissociates and releases Fluo-4; because Fluo-4 is a polar molecule and is not easy to pass through the lipid bilayer membrane, it can keep Fluo-4 in the cell for a long time. Finally, the level of Gα protein activation can be reflected by measuring the intensity of the excited fluorescence. Somatostatin, an agonist of SSTR5, can excite the SSTR5 receptor and greatly increase the calcium flow reaction. The SSTR5 antagonist to be tested can inhibit the agonist activity of the SSTR5 receptor, thereby reducing the calcium flux response that is increased when the receptor is stimulated by the agonist; the GPR40 receptor agonist can excite the GPR40 receptor, thereby greatly increasing the calcium flux response.
[0222] 2) Experimental steps:
[0223] SSTR5 activity test:
[0224] (1) hSSTR5-CHO-Gɑ16 and mSSTR5-CHO-Gɑ16 cell lines stably expressing hSSTR5 or mSSTR5 receptors were seeded at a density of 30,000 cells / well in a 96-well plate and cultured overnight in a 37°C incubator.
[0225] (2) Aspirate the culture medium, add 40 μl / well of freshly prepared dye, and incubate in a 37°C incubator for 45 min.
[0226] (3) Aspirate and discard the dye, wash once with freshly prepared calcium buffer, and then replace with 50 μl calcium buffer.
[0227] (4) Dilute the agonist Somatostatin-14 with calcium buffer and mix well.
[0228] (5) Detection with Flextation instrument. Starting from the 15th second, the instrument automatically adds 25 μl of pre-prepared agonist and finally reads the fluorescence value at 525 nm. Agonist EC 50 The agonist concentration was 9.7 nM, and 100 nM agonist concentration was selected to detect antagonist activity.
[0229] (6) Dilute the positive control antagonist and the test compound with calcium buffer and mix them evenly; wherein the positive control antagonist is 4-(8-((2,6-diethoxy-4'-fluoro-[1,1'-biphenyl]-4-yl)methyl)-3-oxo-2,8-diazaspiro[4.5]dec-2-yl)benzoic acid, which is from the article ACS Med.Chem.Lett.2018,9,1082-1087.
[0230] (7) Aspirate and discard the dye, wash once with freshly prepared calcium buffer, and then replace with 50 μl of 10-fold concentration gradient dilution of antagonist.
[0231] (8) Detection using a Flextation instrument. Starting from the 15th second, the instrument automatically adds 25 μl of a pre-prepared 100 nM agonist and finally reads the fluorescence value at 525 nm.
[0232] GPR40 activity test:
[0233] (1) GPR40-pcDNA3.0 / HEK293 was seeded in a 96-well plate and cultured overnight.
[0234] (2) Aspirate the culture medium, add 40 μl / well of freshly prepared dye, and incubate in a 37°C incubator for 45 minutes.
[0235] (3) Aspirate and discard the dye, wash once with freshly prepared calcium buffer, and then replace with 50 μl calcium buffer.
[0236] (4) Dilute the compound with calcium buffer and mix well.
[0237] (5) Detection by Flextation instrument: 25 μl of pre-prepared compound is automatically added by the instrument starting from the 15th second, and the fluorescence value is finally read at 525 nm.
[0238] 1.2 In vitro activity test results of some compounds
[0239]
[0240] According to Table 1.2, the compounds mentioned above all have the effects of stimulating GPR40 and antagonizing SSTR5. Based on the secretion mechanism of gastrointestinal hormones such as GLP-1, GPR40-SSTR5 dual-effect compounds can theoretically significantly increase the levels of endogenous gastrointestinal hormones such as GLP-1, GIP, PYY, GCG, etc., and are expected to become a new treatment strategy for diseases such as type 2 diabetes and obesity.
Claims
1. A class of GPR40-SSTR5 dual-effect compounds, solvent compounds, hydrates and pharmaceutically acceptable salts thereof as shown in the following general formula I: The A ring is shown in the following structure: X is: -CH2-, -CH(CH3)-, -NH-, -N(CH3)-, or -O-; R5 is H, C1-3 alkyl, C3-C6 cycloalkyl; m, n are integers from 1 to 2; o is an integer from 0 to 2; R1, R2, R3, and R4 are each independently hydrogen, C1-3 alkyl, C1-3 alkoxy, C3-6 cycloalkyl, halogen, trifluoromethyl, trifluoroethyl, hydroxyl, amine, amine substituted with one or two C1-3 alkyl, or substituted or unsubstituted C6-20 aromatic ring; wherein, In the case of a substituted C6-20 aromatic ring, the substituent is halogen, C1-3 alkyl, C3-5 cycloalkyl, hydroxy, amino, amino substituted with one or two C1-3 alkyl, trifluoromethyl, trifluoroethyl or trifluoromethoxy.
2. The compound, solvate, hydrate and pharmaceutically acceptable salt thereof according to claim 1, The A ring is shown in the following structure: X is: -CH2-, -CH(CH3)-, -NH-, -N(CH3)-, or -O-; R5 is H, C1-3 alkyl, or C3-C6 cycloalkyl; m, n are integers from 1 to 2; o is an integer from 0 to 2; R1, R2, R3, and R4 are each independently hydrogen, C1-3 alkyl, C1-3 alkoxy, C3-6 cycloalkyl, halogen, trifluoromethyl, trifluoroethyl, or a substituted or unsubstituted C6-20 aromatic ring; wherein, In the case of a substituted C6-20 aromatic ring, the substituent is halogen, C1-3 alkyl, C3-5 cycloalkyl, hydroxy, trifluoromethyl, or trifluoroethyl.
3. The compound, solvate, hydrate and pharmaceutically acceptable salt thereof according to claim 1, The A ring is shown in the following structure: X is: -NH-, -N(CH3)-, or -O-; R5 is H, or C3-C6 cycloalkyl; m, n are integers from 1 to 2; o is an integer from 0 to 2; R1, R2, R3, and R4 are each independently hydrogen, C1-3 alkoxy, C3-6 cycloalkyl, trifluoromethyl, trifluoroethyl, or a substituted or unsubstituted C6-20 aromatic ring; wherein, In the case of a substituted C6-20 aromatic ring, the substituent is halogen.
4. The compound, solvate, hydrate and pharmaceutically acceptable salt thereof according to claim 1, The A ring is shown in the following structure: X is: -NH-, -N(CH3)-, or -O-; R5 is H, or C3-C6 cycloalkyl; m, n are integers from 1 to 2; o is an integer from 0 to 2; R1, R2, R3, and R4 are each independently hydrogen, C1-3 alkoxy, C3-6 cycloalkyl, trifluoromethyl, trifluoroethyl, or a substituted or unsubstituted C6-20 aromatic ring; wherein, In the case of a substituted C6-20 aromatic ring, the substituent is halogen.
5. The compound, solvate, hydrate and pharmaceutically acceptable salt thereof according to claim 1, wherein: The compound is one of the following compounds:
6. The method for preparing the compound according to claim 1, characterized in that One or more of the following preparation methods are used: Method 1: wherein R1, R2, R3, R4, R5, m, n, and o are as defined in claim 1; Compound L-1 is reacted with different linker fragments L-2 to obtain L-3 through Mitsunobu reaction; L-3 is deprotected under hydrochloric acid or trifluoroacetic acid to obtain L-4; L-4 reacted with different fragments through nucleophilic substitution to give L-5; L-5 was hydrolyzed under alkaline conditions to obtain L-6; Method 2: wherein R1, R2, R3, R4, m, n, and o are as defined in claim 1; Compound L-7 is reacted with methyl bromoacetate via nucleophilic substitution to give L-8; L-8 was deprotected under hydrogen palladium carbon conditions to give L-9; L-9 can be reacted with different linker fragments L-10 to obtain L-11 through Mitsunobu reaction; L-11 is deprotected under hydrochloric acid or trifluoroacetic acid to obtain L-12; L-12 reacted with different fragments through nucleophilic substitution to obtain L-13; L-13 was hydrolyzed under alkaline conditions to obtain L-14; Method 3: wherein R1, R2, R3, R4, m, n, and o are as defined in claim 1; Compound L-15 was reacted with different linker fragments L-16 to obtain L-17 via Mitsunobu reaction; L-17 is deprotected under hydrochloric acid or trifluoroacetic acid conditions to obtain L-18; L-18 reacted with different fragments through nucleophilic substitution to obtain L-19; L-19 was hydrolyzed under alkaline conditions to obtain L-20; Method 4: wherein R1, R2, R3, R4, R5, m, n, and o are as defined in claim 1; Compound L-21 was reacted with different linker fragments L-22 to obtain L-23 via Buchwald reaction; L-23 is deprotected in hydrochloric acid or trifluoroacetic acid to give L-24; L-24 reacted with different fragments through nucleophilic substitution to obtain L-25; L-25 was hydrolyzed under alkaline conditions to obtain L-26; Method 5: wherein R1, R2, R3, R4, R5, m, n, and o are as defined in claim 1; Compound L-27 is reacted under trifluoromethanesulfonic anhydride conditions to obtain L-28; L-28 was reacted with a different linker fragment L-29 to obtain L-30; L-30 is deprotected in hydrochloric acid or trifluoroacetic acid to obtain L-31; L-31 reacted with different fragments through nucleophilic substitution to obtain L-32; L-32 is hydrolyzed under alkaline conditions to obtain L-33; Method 6: wherein R1, R2, R3, R4, R5, m, n, and o are as defined in claim 1; Compound L-34 is reacted under trifluoromethanesulfonic anhydride conditions to obtain L-35; L-35 was reacted with a different linker fragment L-36 to obtain L-37; L-37 is deprotected under hydrochloric acid or trifluoroacetic acid conditions to obtain L-38; L-38 reacted with different fragments through nucleophilic substitution to obtain L-39; L-39 is hydrolyzed under alkaline conditions to give L-40.
7. A pharmaceutical composition comprising the compound of formula I, solvate, hydrate and pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, and a pharmaceutically acceptable carrier.
8. The pharmaceutical composition according to claim 7, further comprising other known drugs for treating type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), gallstones, inflammatory bowel disease, and neurodegenerative diseases, wherein the other drugs include DPP4 inhibitors.
9. Use of the compound of formula I, the solvate, the hydrate and the pharmaceutically acceptable salt thereof according to any one of claims 1 to 5 in the preparation of a drug for preventing or treating a disease mediated by GPR40 and SSTR5; wherein: The diseases mediated by GPR40 and SSTR5 are type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), inflammatory bowel disease, and neurodegenerative diseases.
10. Use of the pharmaceutical composition according to claim 7 or 8 in the preparation of a drug for preventing or treating a disease mediated by GPR40 and SSTR5; wherein: The diseases mediated by GPR40 and SSTR5 are type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), inflammatory bowel disease, and neurodegenerative diseases.
